(Adnkronos) - La nuova modalità di distribuzione dei farmaci che ha trasferito la dispensazione di alcuni antidiabetici dall’ospedale alle farmacie territoriali ha comportato, in un anno, risparmi per 9,7 milioni di euro per il Ssn. Da maggio a novembre 2024, oltre 2 milioni di confezioni gliptine, quindi, centinaia di migliaia di pazienti hanno avuto acceso a farmaci essenziali, senza file in ospedale, senza doppi passaggi in farmacia per la distribuzione per conto e senza barriere burocratiche. È il bilancio tracciato nel corso dell’evento ‘Farmaco accessibile: bilanci e prospettive. Un anno dalla norma’, promosso dal Sottosegretario alla Salute Marcello Gemmato.
Category
🗞
NewsTranscript
00:00A more sustainable health system, without additional costs for citizens and with concrete advantages for all the actors involved,
00:12demonstrating that innovating does not only mean improving services but also optimizing public resources.
00:18This is the result of the new drug distribution model, which has transferred the dispensation of some antidiabetics from hospitals to local pharmacies.
00:27A year after the introduction of the regulation, the Ministry of Health has been tracking the balance of the impact of this measure on public spending and on access to care for citizens.
00:37During the event, accessible drugs, balance and prospects, a year after the regulation, promoted by the Deputy Secretary of Health, Marcello Gemmato.
00:45We have moved a first class of drugs, glyptine, which are antidiabetic drugs, and even instead of having a higher expense,
00:55the AIFA certifies that we have saved 9.7 million euros.
01:00So, better access for the citizen, better compliance, therapeutic adherence and care,
01:08savings for the state coffers, it seems to me an excellent result.
01:12From this regulation, then, the National Health Service has saved about 13% of the costs a year after its introduction.
01:19By the end of the year, an increase is recorded compared to the roof of conventional pharmaceutical spending of about 600 million euros.
01:27The overall impact is positive. Based on these results, the table of monitoring of the Ministry of Health
01:34has ordered the Italian Pharmaceutical Agency to proceed with the identification by March 30 of this year
01:43of a new therapeutic category that can be somehow considered for the transfer, the reclassification from PHT to A.
01:55According to President FISM, Loretto Gesualdo, it is possible to move more accessibility to the drug
02:01directly in the convention to allow the citizen to have a greater proximity.
02:07This means a better quality of life for the patient and also his caregiver.
02:14This will certainly lead to better sustainability of our national health system, reducing direct and indirect costs.
02:23We have seen the results of the first year, they are very encouraging.
02:28We are on the right track, we do not give up, we become a system, we go from a silos system to a horizontal system.
02:36Although there are still margins of further practicability, both pharmacists and citizens have expressed a high level of satisfaction for the implementation of such measures.
02:46From the point of view of the citizens, because it has guaranteed a much easier access to the drug, much closer,
02:53and because it has guaranteed greater assistance continuity from the point of view of the public health service,
03:01also adherence to the cures, because it has guaranteed the possibility of dialogue also with the pharmacist,
03:08which we know is an important element in the relationship of trust that is created between citizens and pharmacies,
03:16in particular in the redesign of the pharmacy of services.